Eythór Björnsson, MD; Guðmar Thorleifsson, PhD; Anna Helgadóttir, MD, PhD; et al.
open access
JAMA Cardiol. 2020;5(1):13-20. doi:10.1001/jamacardio.2019.2946
This genetic study uses data from Icelandic adults who have been genotyped to estimate the contributions of genetically predicted blood lipid levels on the extent of coronary atherosclerosis.
Ply Chichareon, MD; Rodrigo Modolo, MD; Laura Kerkmeijer, MD; et al.
free access
JAMA Cardiol. 2020;5(1):21-29. doi:10.1001/jamacardio.2019.4296
This study assesses the association of sex with patient outcomes at 2 years after contemporary percutaneous coronary intervention and with the efficacy and safety of 2 antiplatelet strategies.
Emily S. Lau, MD; Thomas Cunningham, BA; Kathryn M. Hardin, BA; et al.
free access
JAMA Cardiol. 2020;5(1):30-37. doi:10.1001/jamacardio.2019.4150
This cross-sectional study examines sex differences in cardiometabolic profiles and exercise hemodynamic profiles among individuals with heart failure with preserved ejection fraction.
Alexander C. Fanaroff, MD, MHS; Eric D. Peterson, MD, MPH; Lisa A. Kaltenbach, MS; et al.
free access
JAMA Cardiol. 2020;5(1):38-46. doi:10.1001/jamacardio.2019.4408
This post hoc secondary analysis of a cluster-randomized trial assesses whether providing copayment reduction for P2Y12 inhibitors increases patient persistence in taking other secondary prevention cardiovascular medications.
Rasha Al-Bawardy, MD, MSc; Sreekanth Vemulapalli, MD; Vinod H. Thourani, MD; et al.
free access
JAMA Cardiol. 2020;5(1):47-56. doi:10.1001/jamacardio.2019.4428
This cohort study assesses the association of pulmonary hypertension with clinical outcomes in patients undergoing transcatheter mitral valve repair.
Aylin Ornelas-Loredo; Shinwan Kany, MD; Vihas Abraham, BSc; et al.
free access
JAMA Cardiol. 2020;5(1):57-64. doi:10.1001/jamacardio.2019.4513
This cohort study examines the use of class I and class III antiarrhythmic drug treatment of atrial fibrillation in patients with obesity.
Carlo Fumagalli, MD; Niccolò Maurizi, MD; Sharlene M. Day, MD; et al.
free access
JAMA Cardiol. 2020;5(1):65-72. doi:10.1001/jamacardio.2019.4268
This cohort study describes the association of body mass index with long-term outcomes in patients with hypertrophic cardiomyopathy in terms of overall disease progression, heart failure symptoms, and arrhythmias.
Massimiliano Lorenzini, MD, PhD; Zacharias Anastasiou, MSc; Constantinos O鈥橫ahony, MD, PhD; et al.
free access
JAMA Cardiol. 2020;5(1):73-80. doi:10.1001/jamacardio.2019.4534
This cohort study compares survival among the general European population with that of patients with hypertrophic cardiomyopathy who were recruited from 7 European specialty referral centers.
Lauren A. Eberly, MD, MPH; Sharlene M. Day, MD; Euan A. Ashley, MRCP, DPhil; et al.
free access
JAMA Cardiol. 2020;5(1):83-91. doi:10.1001/jamacardio.2019.4638
This cohort study assesses the association between race, disease expression, care provision, and clinical outcomes among patients with hypertrophic cardiomyopathy.